Service Mark License AmendmentLicense Amendment • June 20th, 2003 • Alestra • Telephone communications (no radiotelephone) • New York
This Service Mark License Amendment (“Agreement”) is made as of the last dated signature below by and between AT&T Corp for itself and for the benefit of each of its Subsidiaries and Affiliates (collectively “AT&T”) and Alestra S. de R.L. de C. V. (“Alestra”).
License AmendmentLicense Amendment • April 11th, 2011 • Brainsway Ltd. • Surgical & medical instruments & apparatus
WHEREAS, the National Institutes of Health (“NIH”), on behalf of the Public Health Service (“PHS”) and the Department of Health and Human Services (“DHHS”), and Brainsway, Inc. (“Licensee”) entered into a license agreement (L-070-2003/0; the “Agreement”) effective August 10, 2003, relating to the Licensed Patent Rights which include DHHS Ref. No. E-223-2000/0-US-03: U.S. Patent Application Ser. No. 10/399,559; DHHS Ref.No. E-223-2000/0-CA-05: Canadian Patent Application Ser. No. 2,425,276; DHHS Ref. No. E-223-2000/0-AU-06; Australian Patent Application Ser. No. 2002229129; DHHS Ref. No. E-223-2000/0-EP-04: European Patent Application Ser. No. 01987684.6; DHHS Ref. No. E-223-2000/0-JP-07: Japanese Patent Application Ser. No. 2002-535740, DHHS Ref. No. E-223-2000/0-IL-08: Israeli Patent Application Ser. No. 155320; and DHHS Ref. No. E-223-2000/0-HK-09: Hong Kong Patent Application Ser. No. 03108947.4, all of which arc entitled “Coil For Magnetic Stimulation” and are national phase applic
License AmendmentLicense Amendment • August 23rd, 2006 • Neopharm Inc • Biological products, (no disgnostic substances)
WHEREAS, the National Institutes of Health (“NIH”), on behalf of the Public Health Service (“PHS”) and the Department of Health and Human Services (“DHHS”), and NeoPharm, Inc. (“Licensee”) entered into license agreement (L-024-2006/0; the “Agreement”) effective May 30, 2006 under which HHS Ref. E-173-1992/0 corresponding to US. Patent 5,720,720; entitled “Convection-Enhanced Drug Delivery,” was licensed nonexclusively to be used for the administration of therapeutics to the central nervous system, including IL-13PE:38QQR compounds and compositions.
